SlideShare a Scribd company logo
The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.
Single-Use
Tangential Flow
Filtration for
Closed Processing
May 6, 2021
The life science business of Merck KGaA,
Darmstadt, Germany operates as
MilliporeSigma in the U.S. and Canada.
Sarah Le Merdy
Strategy Deployment,
Single-Use and Integrated Systems
Dana Kinzlmaier
Applications Engineer
SPEAKERS:
The life science business
of Merck KGaA, Darmstadt,
Germany operates as
MilliporeSigma in the U.S.
and Canada
Agenda
1
2
3
Definitions and drivers
TFF processing in a closed
mode
System characterization
and performance testing
4 Conclusion and
perspectives
Definitions
and drivers
6
What is closed processing about?
Isolating a
product from
the environment
and vice versa
“A process that ensures that biological material does not
come into contact with the external environment. Closed
processing enables grey space or CNC (Controlled Not
Classified) processing and is sometimes referred to as being
conducted in a “ballroom”.
According to ISPE:
“A process condition when the product, materials, critical
components or container/closure surfaces are contained and
separated from the immediate process environment within
closed/sealed process equipment. A process step (or system) in
which the product and product contact surfaces are not exposed
to the immediate room environment.”
BPOG: “The key factor for industry acceptance was the Pharmaceutical
Inspection Cooperation Scheme (PIC/S) determination that clean-room
requirements for bioP can be relaxed/eliminated if your process is closed”.
ISPE Baseline Guide: “The strategy of using uncontrolled or unclassified
spaces for closed piping systems has always been accepted by the
regulatory agencies as an acceptable risk”.
7
FUNCTIONALLY
CLOSED
FULLY CLOSED
BRIEFLY OPEN
SYSTEM
• Never exposed to the environment
• Materials may be introduced to a closed system, in a way to avoid
exposure of the product to the room environment
• Exposes the product to the room environment
• The room environment is controlled to minimize the risk of
product contamination
• For bioburden-controlled processing, open operations are
expected to be performed in a classified environment
• May be routinely opened but returned to a closed state through
a sanitization or sterilization step prior to process use
• Defining and validating the required sanitization or sterilization is
the user's responsibility
Source : Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances
Aug 01, 2011, http://www.biopharminternational.com/challenging-cleanroom-paradigm-biopharmaceutical-manufacturing-bulk-drug-substances?id=&sk=&date=&pageID=2
… and many
different users'
interpretations!
How closed?
Different ways of achieving a closed state
Drivers and benefits
‘Closed’ single-use is an accelerator of single-use benefits
1
Protect from contamination – Ultimately
reducing cleanroom requirements by minimizing
contamination independently from the production
environment
2
Flexibility to market - Means to reduce time to
market using multimodal solutions and/or reducing
turnover time between campaigns, in grey space
3
Reduction of interferences – Limiting the
number of human manipulations and high-risk
open state throughout the process to limit risk of
failure
8
Early and late steps are typically closed by definition
Cell culture, upstream and final fill:
- Closed by design
- Closed by operation
Downstream culture of reuse
- Reusable expendables (TFF devices, chromatography media)
with optimized lifecycle
- Steps still to be converted to single-use operation (clarification)
or with large footprint
Drivers and benefits
Closing what is currently open: Downstream steps
9
Moving downstream steps to single-use and ultimately closed
technologies is a natural next step of the evolution of biomanufacturing
Drivers and benefits
Different drivers lead to closed processing
10
• Manufacturing at ‘point of
use’
• Small, fast set-up capabilities
• Safety of product and patient
“The main objective is the
assurance of an uncompromised
product using a processing
mode which doesn't have
potentially harmful steps.”
• Reduce human interferences
• Reduce environment control
requirements
“The flowpaths used in closed
mode help increasing process
safety and participate to easier,
faster, and lighter
environmental control.”
• Filtration not possible
• Biosafety: no egress
• Animal vaccine never sterile
filtered
Future state:
• Multimodal solutions
• Ballroom concept
Viral vector
& live viruses
Recombinant
proteins
Cell therapy
TFF Processing in
closed mode
Open versus closed processing step
Tighter control and management of inputs and outputs in closed
Open
Multi-use sensors can
be used
Ideally fully automated
‘All’ expendable Similar
to MU processing
‘Open’ lines
authorized,
connect/disconnect
containers
Similar to multi-use
TFF
Similar to multi-
use TFF
Typically class C
SYSTEM &
FLOWPATH
EXPENDABLE SET-UP PROCESSING SAMPLING ENVIRONMENT
Closed
(Fct)
SU sensing
technologies
Aseptic Connectors
Ideally fully auto
Can be sanitized or
sterilized in place
Collecting bags for all
fluids from sanitization
step
Post-sanitization all
fluids in/out are
contained
Closed Potentially lower to
class D
Open allowed post-
product recovery
Closed
(Fully)
Drip-less
disconnections
Are pre-sterilized and
equipped with aseptic
connectors or built in
flowpath
Bags for all fluids from
process start (water,
buffers, waste/drain,
product…)
From set-up to
dismounting all fluids
are contained
Closed, ideally part
of the flowpath
assemblies
Potentially lower to
class D
Potentially ‘never’
open, closed and
dripless
disconnections/
dismounting/
discarding
12
Open:
Connections and
disconnections in a non-sterile
environment during the
different steps in the TFF
operation (flushing, cleaning,
draining, etc)
Flowpath and system design
Closed operation flowpath requires additional fixed lines
WFI Air NaOH Buffer Product
13
Filtrate
Flowpath and system design
Closed operation flowpath requires additional fixed lines
Closed:
Assemblies used for cleaning,
flushing and draining incorporated
into one single assembly (multiple
sub-assemblies mated with aseptic
connectors)
Control of fluid flow during flushing
and draining done with pneumatic
pinch clamps
14
Filtrate
WFI Air NaOH Buffer Product
Functionally closed
- Select any device format
which can be sanitized in place
- Take into account sanitization
agent and flushing volumes
Expendable selection
15
Fully closed
- Select pre-sterilized device
format
- Take into account
connectivity/adaptability to
flowpath
Closed-enabled formats
It is not necessarily about
selecting a ‘new’ or ‘specific’
filtration device type…
System
Characterization and
Performance Testing
Flexware® Assemblies for Closed TFF Processing
Introduction to Equipment used in Experimental Set-up
Mobius® FlexReady System for TFF and Pellicon® Capsule
Mobius® FlexReady
System for TFF
Pellicon® Capsule
& Manifold
Available Recycle Tank Volume [L] 50, 100, 200 -
Membrane Area [m2] 0.5 – 5
0.5 m² - 1.5 m²
Manifold: 1 m²
Multiple of 1.5m²
Flowrate [L/min]
2 – 20
Reco. flowrates for TFF
4-8 L/min/m2
-
Details
Pre-sterilized flowpath
sub-assemblies
Pre-sterilized
ready-to-connect
17
Mobius® FlexReady System for TFF
Fully Closed Flowpath
1 Recycle Vessel Assembly 100 L
2 Transfer Pump Assembly
3 Feed Pump Assembly
4 Transfer Pump Manifold Assembly
5 Smart Flexware® Assembly
6 Pellicon® Capsule Assembly
7 Retentate Sampling Port Assembly
8 Flush/Recovery Assembly
9
Permeate Assembly (with SU sensor
flow cell)
10 Permeate Sampling Port Assembly
1
4
2
3
7
5
8
9
10
6
18
19
Application Testing
System Characterization and Process Testing
1 Minimum working volume
As a function of flow rate and viscosity
2
Flowpath pressure drop
As a function of viscosity
Total pressure drop
Retentate line pressure drop
3 Process run
Concentration and Diafiltration of Human Plasma IgG
4
Product recovery
Low viscosity applications
Elevated viscosity applications
System Characterization
Minimum Working Volume
20
Is the minimum volume at which the system can be operated at given process flowrate without causing air
entrainment in the process fluid. It accounts for volume in the tubing, valves, instruments, membranes, and
minimal volume in the recycle tank.
Why is it important?
To ensure air is not entrained into the system during processing.
Minimum Working Volume
Minimum working volume of flowpath with
1 m2 Pellicon® Capsule assembly at a typical
feed flow rate of 4 - 8 L/min is <1.3 L for
solutions with viscosity between 1 – 50 cP
• Capsule assembly not installed during testing
• Measurements performed with
• Purified Water: 1 cP viscosity
• Glycerin/Purified Water solution:
• 10, 25 and 50 cP viscosity
System Characterization
Total Pressure Drop of the System
21
Total pressure drop of a system is the line drop from the feed pump discharge through the feed lines,
devices and retentate line back to the recycle vessel.
Why is it important?
High Total System Pressure Drop could limit the flow rate that can be driven through devices to increase
mass transfer and drive high flux. It is especially true for high protein concentrations and high viscosity
solutions. • Capsule assembly not installed
during testing
• Measurements performed with
purified water and Mixture of
Glycerin/ Purified Water
Total Pressure Drop of the system in the flow rate
range of 4-8 L/min is less than 6 psi in 1- 50 cP
viscosity range
No significant pressure drop increase due to
added sterile connectors
System Characterization
Retentate Pressure Drop
22
The retentate pressure drop is the line drop from the outlet of the membrane holder through the retentate
line back to the recycle vessel.
Why is it important?
High retentate line pressure drop could limit the minimum transmembrane pressure that can be achieved
even with the retentate control valve fully open.
• Capsule assembly not installed
during testing
• Measurements performed with
Purified Water and Mixture of
Glycerin/ Purified Water
Retentate Pressure Drop in the flow rate
range of 4-8 L/min is less than 5 psi in
1- 50 cP viscosity range
No significant pressure drop increase due
to added sterile connectors
Equilibration Concentration Diafiltration Final concentration Recovery
Closed Processing with Single Use Flexware® Assemblies
and Devices
23
• Equilibration buffer
10 mM PBS, pH 7.2
• 20 L/m2
 18.5 L
 20 g/L to 60 g/L IgG
 Viscosity: 1.5 – 1.8 cP
 Diafiltration at 6 L
 25 mM Sodium
Acetate, pH 5.5
 8 Diavolumes
 60 g/L to 200 g/L IgG
 Viscosity: 1.8 – 13 cP
 Elevated Viscosity
Applications
 Low Viscosity
Applications
 Manual & Automated
All streams have to be collected into bags
Buffer
Product
Waste
Permeate
Product
In
Waste
Retentate
Out
Product Recovery
XV001
XV009
XV003
XV002
XV404
XV102
PCV101
Recycle
Vessel
XV441 XV402 XV431 XV421
XV401
XV411
XV403
XV405
XV007
XV006
XV406
WFI F401 NaOH Buffer Source
Drain
Recovery
Drain
To Flush
Bag
P002
P001
XV004
XV005
PCV001
XV001
XV009
XV003
XV002
XV404
XV102
PCV101
Recycle
Vessel
XV441 XV402 XV431 XV421
XV401
XV411
XV403
XV405
XV007
XV006
XV406
WFI F401 NaOH Buffer Source
Drain
Recovery
Drain
To Flush
Bag
P002
P001
XV004
XV005
PCV001
XV001
XV009
XV003
XV002
XV404
XV102
PCV101
Recycle
Vessel
XV441 XV402 XV431 XV421
XV401
XV411
XV403
XV405
XV007
XV006
XV406
WFI F401 NaOH Buffer Source
Drain
Recovery
Drain
To Flush
Bag
P002
P001
XV004
XV005
PCV001
XV001
XV009
XV003
XV002
XV404
XV102
PCV101
Recycle
Vessel
XV441 XV402 XV431 XV421
XV401
XV411
XV403
XV405
XV007
XV006
XV406
WFI F401 NaOH Buffer Source
Drain
Recovery
Drain
To Flush
Bag
P002
P001
XV004
XV005
PCV001
24
Step 1
Pump the Product out of
the recycle vessel through
the recovery line
Step 2
Gravity Drain the
Retentate Line between
the bottom of the recycle
vessel and transfer line
Step 3
Buffer Flush through the
transfer and retentate lines,
devices to the recovery line
Step 4
Flush the Retentate Line
between the transfer line
and bottom of the recycle
vessel with a small amount
of buffer, then pump it out
through the recovery line
Low Viscosity Applications, Manual Mode of Operation
25
Product Recovery
Protein Recovery Summary
Conc, Pre-Recovery [g/L] 53
Viscosity [cP] 1.6
Yield [%] 102.9
Final Conc [g/L] 47
Step 3 Step 4
Step
1&
2
Elevated Viscosity Applications, Manual Mode of Operation
26
Product Recovery
Protein Recovery Summary
Conc, Pre-Recovery [g/L] 186
Viscosity [cP] 10
Yield [%] 99.0
Final Conc [g/L] 165
Step 3 Step 4
Step
1&
2
27
Product Recovery
Automation: A Key to Process Consistency
Common Control Platform® (CCP®) Software
• Written application recipes can be edited and stored
for different processes
• Report generator quickly creates batch reports
Advantages of Automation
• Run to run consistency
• Lower risk of operator error
• Easier troubleshooting
Product Recovery, Automated Mode
 Product recovery recipes written, tested and
optimized to achieve maximum product recovery
with minimal dilution.
Low Viscosity Applications, Automated Mode of Operation
28
Product Recovery
Protein Recovery Summary
Conc, Pre-Recovery [g/L] 51
Viscosity [cP] 1.5
Yield [%] 97.6
Final Conc [g/L] 44
Step 3 Step 4
Step 1& 2
Elevated Viscosity Applications, Automated Mode of Operation
29
Product Recovery
Protein Recovery Summary
Conc, Pre-Recovery [g/L] 202
Viscosity [cP] 14.5
Yield [%] 94.9
Final Conc [g/L] 170
Step 3 Step 4
Step 1& 2
30
Summary
Closed TFF System and Process Characterization
1
Minimum working volume
• Minimum working volume using 1 m² Pellicon® Capsule assembly
is < 1.3 L for solutions with viscosity between 1 – 50 cP
2
Flowpath pressure drop
• No significant pressure drop increase due to added sterile connectors
• For typical range of flow rates for a TFF process and viscosity 1-50 cp
• Total system: < 6 psi
• Retentate line: < 5 psi
3
Process run
• Protein solutions can be concentrated to high final concentrations
• System can handle processing elevated viscosity solutions with ease
4
Product recovery
• Proposed recovery methods result in ≥ 95% protein recoveries with
minimal protein dilution
• Process can be adjusted to comply with customer specifications and needs
31
A closed state can be achieved in different
ways and would present benefits for
downstream steps.
While drivers vary between applications, the
same specific mindset needs applying to make
it successful with no compromise on
performance.
Ultimately, closed processing steps will be an
integral part of connected, continuous
processing.
Conclusion and
perspectives
sarah.lemerdy@emdgroup.com
dana.kinzlmaier@milliporesigma.com
Sarah Le Merdy
Dana kinzlmaier
The vibrant M, Millipore, Flexware, Mobius and Pellicon are trademarks of Merck KGaA, Darmstadt,
Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed
information on trademarks is available via publicly accessible resources.
© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.
Acknowledgments
Special Thanks to North America MSAT Team, Patrick McGee, Elizabeth Goodrich,
Akshat Gupta, Emily Peterson, Gayathri Raja and Product Marketing Team,
Sylvie Riou and Christophe Dufossé
Thank you

More Related Content

PDF
PVA for sustained release: theory and practice
PPTX
Aseptic Process Sampling to address Risk of Contamination & Containment in co...
PDF
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
PDF
Single-Use Tangential Flow Filtration for Closed Processing
PDF
Validation of Tangential Flow Filtration in Biotech Processes
PDF
Using Single-use Technology to Overcome the Challenges of ADC Processing
PDF
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
PDF
Potential Impact of Draft Annex 1 on Sterilizing Filtration
PVA for sustained release: theory and practice
Aseptic Process Sampling to address Risk of Contamination & Containment in co...
EU GMP Annex 1 – Implications on Filtration and Single Use Technology by Soma...
Single-Use Tangential Flow Filtration for Closed Processing
Validation of Tangential Flow Filtration in Biotech Processes
Using Single-use Technology to Overcome the Challenges of ADC Processing
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
Potential Impact of Draft Annex 1 on Sterilizing Filtration

What's hot (17)

PDF
Find your filter. What’s best for your process?
PDF
Process equipment characterization – how standardized extractables data suppo...
PDF
Better Bioprocessing Efficiency Through Centralized Orchestration
PDF
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
PDF
The Emprove® Program: Introduction of New Portfolio Additions
PDF
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
PDF
Sterile filtration of complex injectables by Partha Banerjee
PDF
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
PDF
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
PDF
Does PUPSIT Reduce Risk for Sterile Filtration?
PDF
Quality by Design Principles Applied to Sterilizing Filtration by Michael Payne
PDF
ADC Production - A Journey made safer and faster
PDF
When Coating runs smoothly: Enhance your Coating Process with a new Particle ...
PDF
Webinar: How a Helium Manufacturing Release Test Increases Integrity Assuranc...
PDF
Reducing Contamination Risk and Improving Product Recovery During Final Steri...
PDF
Excipients selection for high risk formulations Smita Rajput
PDF
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Find your filter. What’s best for your process?
Process equipment characterization – how standardized extractables data suppo...
Better Bioprocessing Efficiency Through Centralized Orchestration
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
The Emprove® Program: Introduction of New Portfolio Additions
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Sterile filtration of complex injectables by Partha Banerjee
Membrane Chromatography Solutions for Single-Use, Intensified mAb Purification
EU GMP Annex 1 Draft: Implications on Sterilizing Grade Filter Validation
Does PUPSIT Reduce Risk for Sterile Filtration?
Quality by Design Principles Applied to Sterilizing Filtration by Michael Payne
ADC Production - A Journey made safer and faster
When Coating runs smoothly: Enhance your Coating Process with a new Particle ...
Webinar: How a Helium Manufacturing Release Test Increases Integrity Assuranc...
Reducing Contamination Risk and Improving Product Recovery During Final Steri...
Excipients selection for high risk formulations Smita Rajput
Next Generation Bioprocessing adoption for mAbs – BioContinuum™ Platform Info...
Ad

Similar to Single-Use Tangential Flow Filtration for Closed Processing (20)

PDF
Find your filter. What’s best for your process?
PPT
Lv1 bio beers pdf
PDF
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
PPTX
PILOT PLANT pratik.pptx
PDF
Pellicon 2
PDF
A Novel Approach to Diafiltration for Intensified or Continuous Processing
PPSX
Parenteral preparation, equipments and layout
PPTX
Process automation in pharmaceutical industry SVP PMT.pptx
PPT
Pilot final 1
PPTX
Aseptic Technique for sterile area .pptx
PDF
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
PPTX
Aseptic filling
PPTX
Presentation1 tff
PDF
Webinar: Novel Perfusion Filter and Controller for N-1 Application
PDF
Webinar: Novel Perfusion Filter and Controller for N-1 Application
PPTX
Pilot plan scale up for semisolid and parenteral by Khushboo kunkulol
PPTX
Pilot plantscaleupof parentrals
PDF
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
PDF
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
PPT
II FILTER LEAF II PHARMACEUTICAL ENGINEERING II BP-304T II
Find your filter. What’s best for your process?
Lv1 bio beers pdf
Implementing and Managing Pre-use Post-sterilization Integrity Testing (PUPSIT)
PILOT PLANT pratik.pptx
Pellicon 2
A Novel Approach to Diafiltration for Intensified or Continuous Processing
Parenteral preparation, equipments and layout
Process automation in pharmaceutical industry SVP PMT.pptx
Pilot final 1
Aseptic Technique for sterile area .pptx
Parvovirus Filtration Best Practices - 25 Years of Hands-On Experience
Aseptic filling
Presentation1 tff
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Pilot plan scale up for semisolid and parenteral by Khushboo kunkulol
Pilot plantscaleupof parentrals
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
Single-Pass Tangential Flow Filtration (SPTFF) Theory and Practice
II FILTER LEAF II PHARMACEUTICAL ENGINEERING II BP-304T II
Ad

More from MilliporeSigma (20)

PDF
Launch of our new Titanium Dioxide Alternative
PDF
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
PDF
Use of Excipients in Downstream Processing to Improve Protein Purification
PDF
Exploring the protein stabilizing capability of surfactants against agitation...
PDF
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
PDF
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
PDF
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
PDF
The Future of Pharma- and Biopharmaceutical Audits
PDF
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
PDF
Identity testing by NGS as a means of risk mitigation for viral gene therapies
PDF
Latest advancements of melt based 3D printing technologies for oral drug deli...
PDF
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
PDF
How does the ICH Q5A revision impact viral safety strategies for biologics?
PDF
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
PDF
Insights from a Global Collaboration Accelerating Vaccine Development with an...
PDF
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
PDF
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
PDF
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
PDF
The Developability Classification System (DCS): Enabling an Optimized Approac...
PDF
How to Accelerate and Enhance ADC Therapies
Launch of our new Titanium Dioxide Alternative
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
Use of Excipients in Downstream Processing to Improve Protein Purification
Exploring the protein stabilizing capability of surfactants against agitation...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Future of Pharma- and Biopharmaceutical Audits
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Latest advancements of melt based 3D printing technologies for oral drug deli...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
How does the ICH Q5A revision impact viral safety strategies for biologics?
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The Developability Classification System (DCS): Enabling an Optimized Approac...
How to Accelerate and Enhance ADC Therapies

Recently uploaded (20)

PPTX
First Aid and Basic Life Support Training.pptx
PPTX
Nancy Caroline Emergency Paramedic Chapter 15
PPTX
Nancy Caroline Emergency Paramedic Chapter 16
PPTX
Vaginal Bleeding and Uterine Fibroids p
PPTX
Nancy Caroline Emergency Paramedic Chapter 13
PPTX
DeployedMedicineMedical EquipmentTCCC.pptx
PPTX
Nancy Caroline Emergency Paramedic Chapter 7
PPTX
Nancy Caroline Emergency Paramedic Chapter 17
PPTX
PE and Health 7 Quarter 3 Lesson 1 Day 3,4 and 5.pptx
PPTX
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
PPTX
Nancy Caroline Emergency Paramedic Chapter 11
PPTX
Theories and Principles of Nursing Management
PDF
Essentials of Hysteroscopy at World Laparoscopy Hospital
PDF
Back node with known primary managementt
PPTX
FUNCTIONS OF BLOOD PART I AND PART 2 WHOLE
PDF
_OB Finals 24.pdf notes for pregnant women
PPTX
unit1-introduction of nursing education..
PPTX
guidance--unit 1 semester-5 bsc nursing.
PPTX
Care Facilities Alcatel lucenst Presales
PPTX
Dissertationn. Topics for obg pg(3).pptx
First Aid and Basic Life Support Training.pptx
Nancy Caroline Emergency Paramedic Chapter 15
Nancy Caroline Emergency Paramedic Chapter 16
Vaginal Bleeding and Uterine Fibroids p
Nancy Caroline Emergency Paramedic Chapter 13
DeployedMedicineMedical EquipmentTCCC.pptx
Nancy Caroline Emergency Paramedic Chapter 7
Nancy Caroline Emergency Paramedic Chapter 17
PE and Health 7 Quarter 3 Lesson 1 Day 3,4 and 5.pptx
General Pharmacology by Nandini Ratne, Nagpur College of Pharmacy, Hingna Roa...
Nancy Caroline Emergency Paramedic Chapter 11
Theories and Principles of Nursing Management
Essentials of Hysteroscopy at World Laparoscopy Hospital
Back node with known primary managementt
FUNCTIONS OF BLOOD PART I AND PART 2 WHOLE
_OB Finals 24.pdf notes for pregnant women
unit1-introduction of nursing education..
guidance--unit 1 semester-5 bsc nursing.
Care Facilities Alcatel lucenst Presales
Dissertationn. Topics for obg pg(3).pptx

Single-Use Tangential Flow Filtration for Closed Processing

  • 1. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Single-Use Tangential Flow Filtration for Closed Processing May 6, 2021
  • 2. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada. Sarah Le Merdy Strategy Deployment, Single-Use and Integrated Systems Dana Kinzlmaier Applications Engineer SPEAKERS:
  • 3. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
  • 4. Agenda 1 2 3 Definitions and drivers TFF processing in a closed mode System characterization and performance testing 4 Conclusion and perspectives
  • 6. 6 What is closed processing about? Isolating a product from the environment and vice versa “A process that ensures that biological material does not come into contact with the external environment. Closed processing enables grey space or CNC (Controlled Not Classified) processing and is sometimes referred to as being conducted in a “ballroom”. According to ISPE: “A process condition when the product, materials, critical components or container/closure surfaces are contained and separated from the immediate process environment within closed/sealed process equipment. A process step (or system) in which the product and product contact surfaces are not exposed to the immediate room environment.” BPOG: “The key factor for industry acceptance was the Pharmaceutical Inspection Cooperation Scheme (PIC/S) determination that clean-room requirements for bioP can be relaxed/eliminated if your process is closed”. ISPE Baseline Guide: “The strategy of using uncontrolled or unclassified spaces for closed piping systems has always been accepted by the regulatory agencies as an acceptable risk”.
  • 7. 7 FUNCTIONALLY CLOSED FULLY CLOSED BRIEFLY OPEN SYSTEM • Never exposed to the environment • Materials may be introduced to a closed system, in a way to avoid exposure of the product to the room environment • Exposes the product to the room environment • The room environment is controlled to minimize the risk of product contamination • For bioburden-controlled processing, open operations are expected to be performed in a classified environment • May be routinely opened but returned to a closed state through a sanitization or sterilization step prior to process use • Defining and validating the required sanitization or sterilization is the user's responsibility Source : Challenging the Cleanroom Paradigm for Biopharmaceutical Manufacturing of Bulk Drug Substances Aug 01, 2011, http://www.biopharminternational.com/challenging-cleanroom-paradigm-biopharmaceutical-manufacturing-bulk-drug-substances?id=&sk=&date=&pageID=2 … and many different users' interpretations! How closed? Different ways of achieving a closed state
  • 8. Drivers and benefits ‘Closed’ single-use is an accelerator of single-use benefits 1 Protect from contamination – Ultimately reducing cleanroom requirements by minimizing contamination independently from the production environment 2 Flexibility to market - Means to reduce time to market using multimodal solutions and/or reducing turnover time between campaigns, in grey space 3 Reduction of interferences – Limiting the number of human manipulations and high-risk open state throughout the process to limit risk of failure 8
  • 9. Early and late steps are typically closed by definition Cell culture, upstream and final fill: - Closed by design - Closed by operation Downstream culture of reuse - Reusable expendables (TFF devices, chromatography media) with optimized lifecycle - Steps still to be converted to single-use operation (clarification) or with large footprint Drivers and benefits Closing what is currently open: Downstream steps 9 Moving downstream steps to single-use and ultimately closed technologies is a natural next step of the evolution of biomanufacturing
  • 10. Drivers and benefits Different drivers lead to closed processing 10 • Manufacturing at ‘point of use’ • Small, fast set-up capabilities • Safety of product and patient “The main objective is the assurance of an uncompromised product using a processing mode which doesn't have potentially harmful steps.” • Reduce human interferences • Reduce environment control requirements “The flowpaths used in closed mode help increasing process safety and participate to easier, faster, and lighter environmental control.” • Filtration not possible • Biosafety: no egress • Animal vaccine never sterile filtered Future state: • Multimodal solutions • Ballroom concept Viral vector & live viruses Recombinant proteins Cell therapy
  • 12. Open versus closed processing step Tighter control and management of inputs and outputs in closed Open Multi-use sensors can be used Ideally fully automated ‘All’ expendable Similar to MU processing ‘Open’ lines authorized, connect/disconnect containers Similar to multi-use TFF Similar to multi- use TFF Typically class C SYSTEM & FLOWPATH EXPENDABLE SET-UP PROCESSING SAMPLING ENVIRONMENT Closed (Fct) SU sensing technologies Aseptic Connectors Ideally fully auto Can be sanitized or sterilized in place Collecting bags for all fluids from sanitization step Post-sanitization all fluids in/out are contained Closed Potentially lower to class D Open allowed post- product recovery Closed (Fully) Drip-less disconnections Are pre-sterilized and equipped with aseptic connectors or built in flowpath Bags for all fluids from process start (water, buffers, waste/drain, product…) From set-up to dismounting all fluids are contained Closed, ideally part of the flowpath assemblies Potentially lower to class D Potentially ‘never’ open, closed and dripless disconnections/ dismounting/ discarding 12
  • 13. Open: Connections and disconnections in a non-sterile environment during the different steps in the TFF operation (flushing, cleaning, draining, etc) Flowpath and system design Closed operation flowpath requires additional fixed lines WFI Air NaOH Buffer Product 13 Filtrate
  • 14. Flowpath and system design Closed operation flowpath requires additional fixed lines Closed: Assemblies used for cleaning, flushing and draining incorporated into one single assembly (multiple sub-assemblies mated with aseptic connectors) Control of fluid flow during flushing and draining done with pneumatic pinch clamps 14 Filtrate WFI Air NaOH Buffer Product
  • 15. Functionally closed - Select any device format which can be sanitized in place - Take into account sanitization agent and flushing volumes Expendable selection 15 Fully closed - Select pre-sterilized device format - Take into account connectivity/adaptability to flowpath Closed-enabled formats It is not necessarily about selecting a ‘new’ or ‘specific’ filtration device type…
  • 16. System Characterization and Performance Testing Flexware® Assemblies for Closed TFF Processing
  • 17. Introduction to Equipment used in Experimental Set-up Mobius® FlexReady System for TFF and Pellicon® Capsule Mobius® FlexReady System for TFF Pellicon® Capsule & Manifold Available Recycle Tank Volume [L] 50, 100, 200 - Membrane Area [m2] 0.5 – 5 0.5 m² - 1.5 m² Manifold: 1 m² Multiple of 1.5m² Flowrate [L/min] 2 – 20 Reco. flowrates for TFF 4-8 L/min/m2 - Details Pre-sterilized flowpath sub-assemblies Pre-sterilized ready-to-connect 17
  • 18. Mobius® FlexReady System for TFF Fully Closed Flowpath 1 Recycle Vessel Assembly 100 L 2 Transfer Pump Assembly 3 Feed Pump Assembly 4 Transfer Pump Manifold Assembly 5 Smart Flexware® Assembly 6 Pellicon® Capsule Assembly 7 Retentate Sampling Port Assembly 8 Flush/Recovery Assembly 9 Permeate Assembly (with SU sensor flow cell) 10 Permeate Sampling Port Assembly 1 4 2 3 7 5 8 9 10 6 18
  • 19. 19 Application Testing System Characterization and Process Testing 1 Minimum working volume As a function of flow rate and viscosity 2 Flowpath pressure drop As a function of viscosity Total pressure drop Retentate line pressure drop 3 Process run Concentration and Diafiltration of Human Plasma IgG 4 Product recovery Low viscosity applications Elevated viscosity applications
  • 20. System Characterization Minimum Working Volume 20 Is the minimum volume at which the system can be operated at given process flowrate without causing air entrainment in the process fluid. It accounts for volume in the tubing, valves, instruments, membranes, and minimal volume in the recycle tank. Why is it important? To ensure air is not entrained into the system during processing. Minimum Working Volume Minimum working volume of flowpath with 1 m2 Pellicon® Capsule assembly at a typical feed flow rate of 4 - 8 L/min is <1.3 L for solutions with viscosity between 1 – 50 cP • Capsule assembly not installed during testing • Measurements performed with • Purified Water: 1 cP viscosity • Glycerin/Purified Water solution: • 10, 25 and 50 cP viscosity
  • 21. System Characterization Total Pressure Drop of the System 21 Total pressure drop of a system is the line drop from the feed pump discharge through the feed lines, devices and retentate line back to the recycle vessel. Why is it important? High Total System Pressure Drop could limit the flow rate that can be driven through devices to increase mass transfer and drive high flux. It is especially true for high protein concentrations and high viscosity solutions. • Capsule assembly not installed during testing • Measurements performed with purified water and Mixture of Glycerin/ Purified Water Total Pressure Drop of the system in the flow rate range of 4-8 L/min is less than 6 psi in 1- 50 cP viscosity range No significant pressure drop increase due to added sterile connectors
  • 22. System Characterization Retentate Pressure Drop 22 The retentate pressure drop is the line drop from the outlet of the membrane holder through the retentate line back to the recycle vessel. Why is it important? High retentate line pressure drop could limit the minimum transmembrane pressure that can be achieved even with the retentate control valve fully open. • Capsule assembly not installed during testing • Measurements performed with Purified Water and Mixture of Glycerin/ Purified Water Retentate Pressure Drop in the flow rate range of 4-8 L/min is less than 5 psi in 1- 50 cP viscosity range No significant pressure drop increase due to added sterile connectors
  • 23. Equilibration Concentration Diafiltration Final concentration Recovery Closed Processing with Single Use Flexware® Assemblies and Devices 23 • Equilibration buffer 10 mM PBS, pH 7.2 • 20 L/m2  18.5 L  20 g/L to 60 g/L IgG  Viscosity: 1.5 – 1.8 cP  Diafiltration at 6 L  25 mM Sodium Acetate, pH 5.5  8 Diavolumes  60 g/L to 200 g/L IgG  Viscosity: 1.8 – 13 cP  Elevated Viscosity Applications  Low Viscosity Applications  Manual & Automated All streams have to be collected into bags Buffer Product Waste Permeate Product In Waste Retentate Out
  • 24. Product Recovery XV001 XV009 XV003 XV002 XV404 XV102 PCV101 Recycle Vessel XV441 XV402 XV431 XV421 XV401 XV411 XV403 XV405 XV007 XV006 XV406 WFI F401 NaOH Buffer Source Drain Recovery Drain To Flush Bag P002 P001 XV004 XV005 PCV001 XV001 XV009 XV003 XV002 XV404 XV102 PCV101 Recycle Vessel XV441 XV402 XV431 XV421 XV401 XV411 XV403 XV405 XV007 XV006 XV406 WFI F401 NaOH Buffer Source Drain Recovery Drain To Flush Bag P002 P001 XV004 XV005 PCV001 XV001 XV009 XV003 XV002 XV404 XV102 PCV101 Recycle Vessel XV441 XV402 XV431 XV421 XV401 XV411 XV403 XV405 XV007 XV006 XV406 WFI F401 NaOH Buffer Source Drain Recovery Drain To Flush Bag P002 P001 XV004 XV005 PCV001 XV001 XV009 XV003 XV002 XV404 XV102 PCV101 Recycle Vessel XV441 XV402 XV431 XV421 XV401 XV411 XV403 XV405 XV007 XV006 XV406 WFI F401 NaOH Buffer Source Drain Recovery Drain To Flush Bag P002 P001 XV004 XV005 PCV001 24 Step 1 Pump the Product out of the recycle vessel through the recovery line Step 2 Gravity Drain the Retentate Line between the bottom of the recycle vessel and transfer line Step 3 Buffer Flush through the transfer and retentate lines, devices to the recovery line Step 4 Flush the Retentate Line between the transfer line and bottom of the recycle vessel with a small amount of buffer, then pump it out through the recovery line
  • 25. Low Viscosity Applications, Manual Mode of Operation 25 Product Recovery Protein Recovery Summary Conc, Pre-Recovery [g/L] 53 Viscosity [cP] 1.6 Yield [%] 102.9 Final Conc [g/L] 47 Step 3 Step 4 Step 1& 2
  • 26. Elevated Viscosity Applications, Manual Mode of Operation 26 Product Recovery Protein Recovery Summary Conc, Pre-Recovery [g/L] 186 Viscosity [cP] 10 Yield [%] 99.0 Final Conc [g/L] 165 Step 3 Step 4 Step 1& 2
  • 27. 27 Product Recovery Automation: A Key to Process Consistency Common Control Platform® (CCP®) Software • Written application recipes can be edited and stored for different processes • Report generator quickly creates batch reports Advantages of Automation • Run to run consistency • Lower risk of operator error • Easier troubleshooting Product Recovery, Automated Mode  Product recovery recipes written, tested and optimized to achieve maximum product recovery with minimal dilution.
  • 28. Low Viscosity Applications, Automated Mode of Operation 28 Product Recovery Protein Recovery Summary Conc, Pre-Recovery [g/L] 51 Viscosity [cP] 1.5 Yield [%] 97.6 Final Conc [g/L] 44 Step 3 Step 4 Step 1& 2
  • 29. Elevated Viscosity Applications, Automated Mode of Operation 29 Product Recovery Protein Recovery Summary Conc, Pre-Recovery [g/L] 202 Viscosity [cP] 14.5 Yield [%] 94.9 Final Conc [g/L] 170 Step 3 Step 4 Step 1& 2
  • 30. 30 Summary Closed TFF System and Process Characterization 1 Minimum working volume • Minimum working volume using 1 m² Pellicon® Capsule assembly is < 1.3 L for solutions with viscosity between 1 – 50 cP 2 Flowpath pressure drop • No significant pressure drop increase due to added sterile connectors • For typical range of flow rates for a TFF process and viscosity 1-50 cp • Total system: < 6 psi • Retentate line: < 5 psi 3 Process run • Protein solutions can be concentrated to high final concentrations • System can handle processing elevated viscosity solutions with ease 4 Product recovery • Proposed recovery methods result in ≥ 95% protein recoveries with minimal protein dilution • Process can be adjusted to comply with customer specifications and needs
  • 31. 31 A closed state can be achieved in different ways and would present benefits for downstream steps. While drivers vary between applications, the same specific mindset needs applying to make it successful with no compromise on performance. Ultimately, closed processing steps will be an integral part of connected, continuous processing. Conclusion and perspectives
  • 32. sarah.lemerdy@emdgroup.com dana.kinzlmaier@milliporesigma.com Sarah Le Merdy Dana kinzlmaier The vibrant M, Millipore, Flexware, Mobius and Pellicon are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Acknowledgments Special Thanks to North America MSAT Team, Patrick McGee, Elizabeth Goodrich, Akshat Gupta, Emily Peterson, Gayathri Raja and Product Marketing Team, Sylvie Riou and Christophe Dufossé Thank you